Hirepa 2mg Tablet contains Repaglinide 2mg, an oral antihyperglycemic agent belonging to the meglitinide class, primarily indicated for the management of type 2 diabetes mellitus. Repaglinide acts by stimulating pancreatic beta cells to release insulin, thereby facilitating improved glycemic control postprandially. It is particularly effective in reducing post-meal blood glucose spikes and is often prescribed as part of a comprehensive diabetes management plan including diet and exercise. The rapid onset and short duration of action of Repaglinide allow flexible dosing with meals, minimizing the risk of prolonged hypoglycemia. Hirepa 2mg is suitable for patients inadequately controlled by diet alone or those who require additional glycemic control without the long-lasting effects associated with sulfonylureas. The medication should be administered shortly before meals to optimize efficacy. Common adverse effects may include hypoglycemia, headache, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision with regular monitoring of blood glucose levels. Hirepa 2mg Tablet offers an effective option for individualized diabetes therapy aimed at achieving target glycemic goals and reducing the risk of diabetes-related complications.